Besides traditional monoclonals, innovative antigen-specific tools called “nanobodies” have been developed to inhibit NRP1 function, and proven to be effective in sensitizing drug-resistant cancer cells to oncogene-targeted therapies [43]. The gene discussed is NRP1; the disease is cancer.